T1	Treatment 11 47	sodium and potassium supplementation
T2	Treatment 227 263	sodium and potassium supplementation
T3	Treatment 501 678	received capsules with supplemental sodium (3 g d(-1), equals 7.6 g d(-1) of salt), supplemental potassium (3 g d(-1)) or placebo, for 4 weeks each, in random order.
T4	Treatment 679 787	Fasting office BP, 24-h ambulatory BP and measures of arterial stiffness were assessed at baseline and every
T5	Treatment 1071 1093	compared with placebo.
T6	Treatment 1094 1100	During
T7	Treatment 1218 1249	central BP by 8.5/3.6 mm Hg
T8	Treatment 1409 1459	augmentation index were not significantly affected
